- 재진방문을 하지 않은 두통 환자의 원인 및 경과에 대한 후향적 분석
-
Hyun-Jung Park, Ji-young Shim, Sun-hee Whang, Suk-Hee Kim, Jong-Ha Park, Soon-Tae Lee, Kon Chu, Man-ho Kim
-
Korean J Headache. 2006;7(1):37-40. Published online June 30, 2006
-
-
-
 Abstract
 PDF
- Background
The lost to follow-up is frequent among the patients w ith headache, but the extent or the reasons is unknown. To determine the frequency and the reason for the loss to follow-up, and to further evaluate the clinical course of headache w ithout m edication. Objects and M ethod s: Consecutive patients w ith headache visited the headache clinic in SNU H ospital w ere retros-pectively analyzed. Lost to the follow-up (LF) is determined w ho didn't m ake a re-visit following the prescription. Demographic characteristics, headache subtypes, and the reasons for the w ithdraw al w ere recorded by m edical record or telephone survey.
Results
1,090 patients w ith LF w ere evaluated (61.4% ). Sex ratio w as not different between LF group and follow-up group (men 24.0% , women 76.0% for LF). A ge distribution shows two folds higher in 20s and 30s when compared to follow-up group (5.6% 20s, 12.1% 30s for LF; 3.1% 20s, 6.4% 30s for follow-up). M igraine w as 17.6 times higher than the patients w ith tension type headache. The reasons for the LF were, ① improvem ent 35.8%, ② adverse event 12.0%, ③ no improvem ent 17.7% , ④ visit another hospital 5.0% , ⑤ etc 1.3% . Further analysis with the patients w ithout medications showed that ① headache aggravated 6.4% , ② stationary 45.4%, ③ improvement 23.3%, ④ unknown 24.9%.
Conclusions
Improvement is the m ost common reason for the LF. The outcom e w ithout m edication w as variable, suggesting it m ust be considered at a clinical research analysis. Korean Journal of Headache 7(1):37-40, 2006
- 고혈압을 동반한 편두통 환자에서 칼슘통로 길항제 Lercanidipine의 두통빈도 감소 효과에 대한 전향적 공개 임상 연구
-
Soon-Tae Lee, Jeung-Eun Park, Hyun-Jung Park, Ji-Young Sim, Sun-Hi Hwang, Jong-Ha Park, Lami Kang, Manho Kim
-
Korean J Headache. 2005;6(2):149-153. Published online December 31, 2005
-
-
-
Abstract
PDF
- Background
Anti-hypertensive medication is commonly used for the prophylaxis of migraine headache. Calcium channel blockers, verapamil, flunarizine, nimodipine or nifedipine have been tried as anti-migraine drug. Lercanidipine is developed as anti-hypertensive drug in Korea with high lipid solubility and longer duration of action. In this study, we attempted to test the efficacy of lercanidipine for the migraine with hypertension in an open labeled prospective study.
Patients and Methods: Consecutive 107 outpatients aged 20 to 70 years (mean, 61.4±9.9), were analyzed. Diagnosis of migraine was made according to the International Headache Society criteria, and the migraineurs were assigned to treatment with lercanidipine (10 mg/day) for 12 weeks. The efficacy variables included the changes in monthly headache frequency, Headache Management Self-Efficacy Scale (HMSE), and Headache Disability Inventory (HDI).
Results
Headache frequency showed 62.5% reduction for three months with responder rate of 73%. HMSE score showed an improvement whereas HDI scores remaind unchanged.
Conclusions
Lercanidipine is an effective prophylactic agent in migraine. A double-blind placebo-controlled clinical trial is warranted. Korean Journal of Headache 6(2):149-153, 2005
|
KHS
